larynx cancer
Recently Published Documents


TOTAL DOCUMENTS

341
(FIVE YEARS 72)

H-INDEX

24
(FIVE YEARS 4)

2021 ◽  
pp. 019459982110492
Author(s):  
Rohith S. Voora ◽  
Bharat A. Panuganti ◽  
Mitchell Flagg ◽  
Tyler Nelson ◽  
Nikhil V. Kotha ◽  
...  

Objective Recurrence is known to predict laryngeal squamous cell cancer (LSCC) survival. Recurrence patterns in T4a LSCC are poorly characterized and represent a possible explanation for observed survival discrepancies by treatment rendered. Study Design Retrospective database review. Setting Veterans Affairs national database. Methods Patients with T4a LSCC between 2000 and 2017 were identified and stratified by treatment (chemoradiotherapy [CRT] vs total laryngectomy + neck dissection + adjuvant therapy [surgical]). Primary outcomes were locoregional and distant recurrence. Secondary outcomes of overall mortality, larynx cancer mortality, and noncancer mortality were evaluated in Cox and Fine-Gray models. Results A total of 1043 patients had comparable baseline demographics: 438 in the CRT group and 605 in the surgical group. Patients undergoing CRT had higher proportions of node positivity (64.6% vs 53.1%, P < .001). Locoregional and distant recurrence were less common in the surgical group (23.0% vs 37.2%, P < .001; 6.8% vs 13.3%, P < .001, respectively); however, distant metastatic rates did not differ within the N0 subgroup ( P = .722). On multivariable regression, surgery demonstrated favorable locoregional recurrence (hazard ratio [HR], 0.49; 95% CI, 0.39-0.62; P < .001), distant recurrence (HR, 0.47; 95% CI, 0.31-0.71; P < .001), overall mortality (HR, 0.75; 95% CI, 0.64-0.87; P < .001), and larynx cancer mortality (HR, 0.69; 95% CI, 0.56-0.85; P < .001). Conclusion T4a LSCC survival discrepancies between surgical and nonsurgical treatment are influenced by varying recurrence behaviors. Surgery was associated with superior disease control and improved survival. Beyond the known benefit in locoregional control with surgery, there may be a protective effect on distant recurrence that depends on regional disease burden.


2021 ◽  
Vol 163 ◽  
pp. S18
Author(s):  
Nauman Malik ◽  
Nicolin Hainc ◽  
Gia Gill ◽  
Steven Nakoneshny ◽  
Paul Kerr ◽  
...  

2021 ◽  
Vol 20 (4) ◽  
pp. 21-29
Author(s):  
L. D. Zhuikova ◽  
E. L. Choynzonov ◽  
O. A. Ananina ◽  
A. S. Zhuikova ◽  
T. V. Polychuk

Introduction. A significant component in the system analysis of anti-cancer activities is the assessment of the impact of mortality on life expectancy, which indicates the social and economic situation in the region.Material and methods. The economic damage caused by laryngeal and lung cancer mortality in the Tomsk region for the period 2005–2016 was analyzed using the database of the regional cancer registry and local agency of federal state statistics service of the tomsk region.Results. The loss of the male working population ranged from 106.0 (2012–2013) to 161.5 (2008–2009) person/years of lifetime from larynx cancer and from 1058.5 (2013–2014) to 1576.3 (2006–2007) person/years of lifetime from lung cancer. The female working population lost up to 34.0 (2013–2014) person/years of lifetime due to mortality from larynx cancer and from 1445.3 (2005–2006) to 2553.9 (2015–2016) person/years of lifetime from lung cancer. The average number of undelivered years in working age due to the premature death of one man averaged 6.1 ± 2.0 years from larynx cancer and 11.1 ± 1.3 from lung cancer, one woman averaged 4.6 ± 0.9 years from larynx cancer and 6.2 ± 0.3 years from lung cancer. Economic losses associated with mortality from cancer of the respiratory system amounted to 2.251.97 million rubles: 202.07 million rubles from laryngeal cancer and 2.049.90 million rubles from lung cancer.Conclusion. The quantitative analysis of social and economic losses associated with mortality from cancer of the respiratory system enables the regional health authorities to develop and implement anti-cancer interventions to maximize the use of funds for the prevention, treatment and rehabilitation of cancer patients.


Oral Oncology ◽  
2021 ◽  
Vol 118 ◽  
pp. 6
Author(s):  
Thomas Brunner ◽  
Herbert Wördehoff ◽  
Ahmed Gawish ◽  
Christoph Arens ◽  
Uwe Busch

2021 ◽  
pp. 000348942110240
Author(s):  
Tirth R. Patel ◽  
Jaijeet Toor ◽  
Bobby A. Tajudeen ◽  
Mihir Bhayani ◽  
Samer Al-Khudari

Objective: Salvage laryngeal surgery is the preferred treatment after failure of non-surgical treatment of larynx cancer. This study aims to identify the impact of ND in salvage surgery on survival and factors predictive of nodal metastasis. Methods: The National Cancer Database was used to identify patients who received salvage laryngeal surgery. Demographics, disease characteristics, and survival were compared between the subgroups of patients stratified according to performance of ND and presence of nodal metastasis. Results: Sixty-two percent of patients underwent ND. A total of 26% of patients undergoing ND had nodal metastasis. Younger age and lesser time since radiation were associated with nodal metastasis. While undergoing ND did not significantly affect survival, those with nodal metastasis had poorer survival ( P = .001). Conclusions: Although ND did not show a survival benefit, younger patients and those who have had a shorter time elapsed between the start of radiation and salvage surgery may benefit from the prognostic data provided by ND. Nonetheless, the risks and benefits of elective ND in salvage larynx cancer treatment should be evaluated on an individual case basis as the data do not support a broadly applicable recommendation.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18044-e18044
Author(s):  
Nauman Malik ◽  
Nicolin Hainc ◽  
Gia Gill ◽  
Steven Nakoneshny ◽  
Paul Kerr ◽  
...  

e18044 Background: Organ preservation approaches to treatment of locally advanced larynx cancers are widely used and consist of radiotherapy (RT) with or without concurrent systemic therapy (CRT). Analyses of the National Cancer Database point to decreasing survival as CRT became widely adopted in place of total laryngectomy (TL). Tumor volume in T3 laryngeal tumors has been postulated as one variable to explain this finding, with higher volume associated with lower local control based on small sample size studies largely in pre-intensity modulated radiotherapy (IMRT) era, and low volume T3 tumors being associated with improved local control with CRT. We sought to validate these findings in a contemporary cohort of T3 larynx patients treated with IMRT. Methods: This was a national, multicentre retrospective cohort study of patients diagnosed with American Joint Committee on Cancer (AJCC) T3 N0-3 M0 glottic and supraglottic cancers who underwent curative intent IMRT with or without systemic treatment from 2002-2018. Tumor volumes were calculated using a validated standardized approach by a Neuroradiologist. Primary predictor was tumor volume, primary outcome was local control (LC), and secondary outcomes included overall survival (OS), as well as late grade 3+ toxicities. Kaplan Meier estimates and log-rank tests were used for survival analyses, with Cox proportional hazards used for univariable analyses. Results: 246 patients met inclusion criteria, 147 glottic and 99 supraglottic cancers. At baseline, glottic patients were more likely to be male (p < 0.01), have a fixed vocal cord (p < 0.01), not have pre-epiglottic space invasion ( < 0.01), be cN0 (p < 0.01), and have lower grade tumors (p < 0.01). Mean tumor volumes for glottic and supraglottic tumors were 5.0 (4.2-5.8) cc and 13.0 (10.3–15.6) cc respectively. Univariable analysis showed systemic therapy was associated with improved local failure (HR 0.49, 95%CI 0.24 – 0.99, p = 0.05). Within the glottic cohort, tumor volume was not associated with local failure (HR 1.09, 95%CI 0.71 – 1.67, p = 0.38), however having a local failure event was associated with increased feeding tube dependence (HR 2.52, 95%CI 1.05 – 6.02, p = 0.04). Median local failure free survival in the overall cohort was 28.5 months, with median OS 23.2 months. There was a trend towards improved local control in the supraglottic cohort compared to glottic patients (log-rank p = 0.08), but the supraglottic cohort had significantly worse overall survival (log-rank p = 0.02). Conclusions: In this retrospective cohort study, there were baseline and outcome differences between patients with T3 glottic and supraglottic larynx cancer, with worse overall survival in supraglottic patients. Tumor volume was not associated with local control in the glottic cohort. These findings are pending further validation in a larger cohort and will be analyzed separately for supraglottic tumors.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18006-e18006
Author(s):  
Rohith S. Voora ◽  
Bharat Panuganti ◽  
Mitchell Flagg ◽  
Abhishek Kumar ◽  
Nikhil V. Kotha ◽  
...  

e18006 Background: Both chemoradiotherapy (CRT) and total laryngectomy (TL) with adjuvant therapy are curative-intent treatment options for patients with T4a larynx cancer. Disease recurrence is a known negative prognosicator, but differences in recurrence patterns and the subsequent survival associations are not well characterized. To address this knowledge gap, we present long-term recurrence and survival outcomes from a novel longitudinal data source. Methods: Retrospective study of non-metastatic T4a larynx cancer patients diagnosed between 2000-2017 who underwent curative-intent treatment (TL with adjuvant therapy or primary CRT) from the VA Informatics and Computing Infrastructure database. Adjuvant therapy consisted of either postoperative radiotherapy (RT) or CRT. Fine-Gray and Cox models were used to evaluate primary outcomes – time to locoregional recurrence and distant recurrence. Secondary outcomes included overall survival (OS), cancer-specific survival (CSS), non-cancer specific survival (NCSS), and disease-free survival (DFS). These multivariable models accounted for age, race, alcohol history, smoking status, education and income, Charlson-Deyo score, N-classification, and tumor subsite. Results: The study included 1,114 patients with a median follow-up time of 63.3 months among those alive at last follow up. In the TL group, adjuvant RT was used in 69% and adjuvant CRT was used in 31%. Median time to first recurrence was 24.4 months with overall incidence of 28.5% locoregional and 9.5% distant recurrence. Primary CRT patients had higher rates of locoregional (37.2 vs. 22.9%) and distant recurrence (13.3 vs. 7.0%) (p < 0.0001). Median OS was 27.3 months for CRT (95% CI: 23.6-32.4 months) and 47.5 months (95% CI: 39.6-52.1 months) for TL. Median DFS was 14.1 months for CRT (95% CI:12.5-17.2 months) and 37.9 months (95% CI 31.2-47.5 months) for TL. On multivariable analysis compared to CRT, TL was associated with longer time to locoregional (HR 0.50, 95% CI:0.40-0.61) and distant recurrence (HR 0.50, 95% CI:0.34-0.73). Having N+ disease increased risk of distant recurrence (HR 2.20, 95% CI:1.42-3.41). TL was associated with improved OS (HR 0.78, 95% CI:0.67 – 0.91), CSS (HR 0.73, 95% CI:0.59 – 0.89), and DFS (HR 0.58, 95% CI 0.49-0.69) compared to CRT; NCSS was equivalent between groups (HR 1.09, 95% CI:0.88-1.35). Of the CRT patients with locoregional failures, 67/163 (41.1%) were salvaged with surgery. Conclusions: In this cohort of T4a larynx cancer patients, surgical management demonstrated favorable recurrence and survival results. TL with adjuvant therapy was associated with significantly lower incidence of both locoregional and distant recurrence and increased OS, CSS and DFS compared to CRT. Lower probability of disease recurrence, in addition to a survival advantage, should be considered as an important advantage to up-front surgery.


Sign in / Sign up

Export Citation Format

Share Document